FDA just made cancer tests way less extra
An FDA rule change slashes regulatory costs from $4 million to $30,000 per diagnostic device, accelerating oncology testing.
By Foodie Pundit Newsroom - Published - Updated - Section: Policy Regulation
Key points
- The FDA has lowered the regulatory requirements for a class of oncology diagnostic tests, moving them from high-risk Class III to moderate-risk Class II.
- This reclassification, detailed in the Federal Register, is intended to reduce the time and cost for manufacturers to bring new cancer tests to market.
- The rule change does not name or benefit a specific company but applies to the entire medical device industry in this space.
- The authority for this decision rests solely with the FDA, which is exercising its power to regulate medical devices based on risk.
- The next milestone is the rule's effective date of September 16, 2026, after which companies can use the new, streamlined process for approval.
This report is part of Foodie Pundit premium coverage. Foodie Pundit members read the full story. See membership.